[Clinical and Pathological Study on Effects of Qianggan Capsule Combined Lamivudine on Hepatic Fibrosis in Patients with Chronic Hepatitis B]
Overview
Authors
Affiliations
Objective: To study the therapeutic effects of Qianggan Capsule (QC) combined Lamivudine on hepatic fibrosis in patients with chronic hepatitis B.
Methods: Eighty-five patients were randomly divided into two groups, group A (40 cases) were treated with QC and Lamivudine and group B (45 cases) were treated with QC alone both for 6 months. Hepatic fibrosis related indexes and pathologic examination of liver biopsy were performed within 3 months before treatment and in 1 month after treatment.
Results: Serum levels of hyaluronic acid, collagen N and laminin decreased markedly after treatment in both groups (P < 0.05). Hepatic histopathological examination showed that the total effective rate of impovement in activity of inflammation-necrosis and fibrosis was 80.0% and 70.0% in group A, 57.8% and 75.6% in group B, respectively, the combined treatment showed a better effect in improving the activity of inflammation-necrosis than QC alone (P < 0.05), but with no significant difference to the latter in improving fibrosis.
Conclusion: QC combined Lamivudine could markedly reduce the activity of hepatic inflammation-necrosis, QC alone could also improve hepatic fibrosis.
Yang L, Wang H, Yan H, Wang K, Wu S, Li Y Molecules. 2022; 27(10).
PMID: 35630700 PMC: 9143483. DOI: 10.3390/molecules27103223.
Zhu M, Li M, Zhou W, Yang Y, Li F, Zhang L BMC Complement Altern Med. 2019; 19(1):156.
PMID: 31269941 PMC: 6609373. DOI: 10.1186/s12906-019-2577-6.
Long L, Xue C, Shi J, Dong J, Wang L Hepat Mon. 2015; 15(7):e29052.
PMID: 26300933 PMC: 4539848. DOI: 10.5812/hepatmon.29052v2.